Spotlight Stories

  1. Imagine Pharma's Multilayered Path To Market 10/3/2022

    From the looks of its modest open floor plan lab in Pittsburgh’s uptown, it might not be obvious to the casual observer that Imagine Pharma and its nine-person full-time workforce are developing multiple pharmaceutical products across three distinct platforms.

  2. The Discovering CEO 10/3/2022

    In the current world of biopharma companies, the discovery function covers much more than hammering out new drug entities.

  3. Nonprofit Pursues Oncology Drugs 9/1/2022

    RebootRX believes that many off-patent pharmaceuticals have cancer-fighting potential, but their generic status makes them unattractive commercial candidates for profit-making pharmas.

  4. Conducting A Drug Development Orchestra To Treat Mental Illness 9/1/2022

    Karuna Therapeutics’ late-stage drug for schizophrenia, if approved, could fund the company’s pipeline of next generation psychiatric drugs discovered through a modular constellation of CRO partners.

  5. Bayer Brings External Innovation Inside, With Guardrails 9/1/2022

    Can Bayer’s “arm’s-length model” for acquired companies help turn the century-and-a-half year-old Big Pharma into a leader in gene and cell therapy, and a top 10 player in oncology?

  6. Alnylam's Challenge: Scaling Up And Moving Beyond The Liver 8/1/2022

    Alnylam CEO Yvonne Greenstreet talks about what’s next for the company, including a transition into larger therapeutic areas and patient populations, and describes her own journey to the CEO role.  

  7. KemPharm: Converting FDA Complete Response Letters Into New Opportunities 8/1/2022

    KemPharm’s experience in reworking product NDAs following FDA Complete Response Letters has created a unique capability within the company, and helped it move to acquire a potentially valuable asset from distressed biopharma Orphazyme.

  8. Living Diversity, Inside Mink Therapeutics 8/1/2022

    We sought out a biopharma enterprise where diversity always has been an operating principle, where it feeds the company’s intellectual life and creative culture, and where it is demonstrable yet still evolving.

  9. A Network And Pivot Model For Success In Cancer Drug Development 7/1/2022

    When CEO Avanish Vellanki founded and incorporated Rain Therapeutics on his living room couch in the spring of 2017, there was no drug in development, no money, and a team of only four people.

  10. New Space For Bio In Transplantation 7/1/2022

    Jasper Therapeutics and other bio companies may revolutionize hematopoietic stem cell therapy (HSCT) — a feat with profound effects on the biopharma and hospital-based hematology sectors alike.